Tanya Voloshen, CCO joins IXICO as a member of the Senior Leadership Team with deep commercial and executive leadership experience in the neuroimaging market
05 February 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has appointed Tanya Voloshen as Chief Commercial Officer (CCO) based in Boston, Massachusetts (USA).
Tanya joins IXICO from Perceptive Inc. a global contract research organisation (CRO) where she held the role as SVP Commercial. Prior to joining Perceptive, Tanya held senior commercial leadership roles for international clinical trial and medical technology companies with a focus on neuroscience and medical imaging including Clario (now part of Thermo Fisher Scientific), QMENTA and ConcertAI. Tanya started her career in the pharmaceutical industry working for Johnson & Johnson and Sanofi.
Bram Goorden, Chief Executive Officer of IXICO, commented: “I am very pleased to welcome Tanya to IXICO as CCO, a newly appointed position in the senior leadership team that reflects a firm and continued commitment to strengthen our commercial capabilities and accelerate growth. Based in Boston, Tanya brings strong commercial leadership experience, established customer relationships and an excellent understanding of the critical contribution that IXICO’s technology platform can make in the clinical imaging market.”
